Skip to main content

Table 1 Qualitative interview participant demographics and clinical characteristics (N = 40)

From: Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates

 

Patients

Advocates

 

n = 24

n = 16

 

n (%)

n (%)

Age (median, IQR)

 Median

57

61

 Range

33–79

36–75

Race

 Black or African American

10 (41.7)

2 (12.5)

 White

14 (58.3)

14 (87.5)

Highest level of education

 High School

5 (20.8)

0 (0.0)

 Some college/Vocational or Technical School

9 (37.5)

2 (12.6)

 College graduate (4 year)

7 (29.2)

5 (31.3)

 Master’s degree or Professional degree

2 (8.3)

8 (50.0)

 Other

1 (4.2)

1 (6.3)

Rural/Urban Commuting Area (based on zip code)

 Rural

2 (8.3)

 Urban

15 (62.5)

 Unassigned/unanswered

7 (29.2)

16 (100.0)

Area Deprivation Index (based on zip code)

 Low

3 (12.5)

 Mid

7 (29.2)

 High

7 (29.2)

 Unassigned/unanswered

7 (29.2)

16 (100.0)

Marital status

 Single, Unmarried, living with significant other

5 (20.8)

3 (18.8)

 Married

14 (58.3)

13 (81.3)

Preference for treatment decision-making style (Control Preferences Scale)

 Patient-driven decision making

1 (4.2)

0 (0.0)

 Patient-driven decision making with provider input

5 (20.8)

9 (56.3)

 Shared decision-making

14 (58.3)

6 (37.5)

 Physician-driven decision-making with patient input

2 (8.3)

1 (6.3)

 Physician-driven decision-making

1 (4.2)

0 (0.0)

 Missing

1 (4.2)

0 (0.0)

Breast cancer diagnosis stage

 II

16 (66.7)

 III

8 (33.3)

Breast cancer type

 ER/PR + HER2-

8 (33.3)

 ER/PR- HER2 + 

11 (45.8)

 ER/PR- HER2-

5 (20.8)

  1. IQR interquartile range, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2